Skip to content

Use of a Dual-agent Local Analgesic (Bupivacaine-meloxicam) for Abdominal Incisions in Patients Undergoing Retropubic Mid-urethral Sling Surgery

Use of a Dual-agent Local Analgesic (Bupivacaine-meloxicam) for Abdominal Incisions in Patients Undergoing Retropubic Mid-urethral Sling Surgery

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05702827
Enrollment
148
Registered
2023-01-27
Start date
2023-01-23
Completion date
2024-04-18
Last updated
2024-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stress Urinary Incontinence, Surgical Incision, Pain Vulva

Brief summary

This study will compare the use of a dual-agent local analgesic (bupivacaine-meloxicam) for abdominal incisions in patients undergoing retropubic mid-urethral sling surgery to see if narcotic usage and pain are impacted.

Interventions

All patients will receive standard of care but the study arm will also receive Bupivacaine-Meloxicam in addition.

Sponsors

TriHealth Inc.
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* undergoing retropubic mid-urethral sling surgery (with concomitant anterior repair or urethrocele repair) * English as first language

Exclusion criteria

* patients undergoing concomitant posterior repair, vaginal vault suspension, or any other intra-peritoneal surgeries including hysterectomy * NSAID use within 7 days of surgery * steroid use within 10 days * daily opioid use in the last 3 months * long acting opioids within 3 days * any opioids within 24h * patients unable to consent for themselves * patients allergic to meloxicam or bupivacaine * pregnant or lactating patients

Design outcomes

Primary

MeasureTime frameDescription
To determine if use of bupivacaine-meloxicam reduces post-operative narcotic use over the first 3 days following surgery72 hours post surgeryPain medication diary

Secondary

MeasureTime frameDescription
Compare average pain on each day post operatively72 hours post surgery11-point Numeric Rating Scale (NRS) for tracking pain using an illustrated figure to localize the pain, a 5-point Likert scale for satisfaction with pain control a Quality of Recovery (QoR-15) questionnaire filled out before surgery and on post-operative days 1 and 3
Compare worst pain on each day post operatively72 hours post surgery11-point Numeric Rating Scale (NRS) for tracking pain using an illustrated figure to localize the pain, a 5-point Likert scale for satisfaction with pain control a Quality of Recovery (QoR-15) questionnaire filled out before surgery and on post-operative days 1 and 3
Compare satisfaction with pain control post operatively72 hours post surgery11-point Numeric Rating Scale (NRS) for tracking pain using an illustrated figure to localize the pain, a 5-point Likert scale for satisfaction with pain control a Quality of Recovery (QoR-15) questionnaire filled out before surgery and on post-operative days 1 and 3

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026